Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01322802 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
A Phase 1 study of Stage IV Ovarian Epithelial Cancer and Stage III Ovarian Epithelial Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01322802: Completed Phase 1 study of Stage IV Ovarian Epithelial Cancer and Stage III Ovarian Epithelial Cancer, sponsored by University of Washington.
NCT01322802 is a Phase 1 study of Stage IV Ovarian Epithelial Cancer and Stage III Ovarian Epithelial Cancer that has completed, run by University of Washington. The registered enrollment target is 25 participants, below the 39-participant average among 4 other Stage IV Ovarian Epithelial Cancer trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01322802, a Phase 1 study of Stage IV Ovarian Epithelial Cancer and Stage III Ovarian Epithelial Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects of vaccine therapy in treating patients with stage III-IV or recurrent ovarian cancer. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells.
Primary Outcome
Demographic and background characteristics obtained at enrollment will be listed and summarized. The type and grade of toxicities noted during the immunization regimen will be summarized. All adverse events noted by the investigator will be tabulated according to the affected body system. Descriptive statistics will be used to summarize changes from baseline in clinical laboratory parameters.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-03-06 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 1 |
What the finished NCT01322802 record still lists
NCT01322802 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 39-participant average among 4 other Stage IV Ovarian Epithelial Cancer trials with a reported enrollment target (36% lower).
The record links to 4 conditions, with Stage IV Ovarian Epithelial Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01322802 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01322802 about?
NCT01322802 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer". This phase I trial is studying the side effects of vaccine therapy in treating patients with stage III-IV or recurrent ovarian cancer. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells.
What is the current status of trial NCT01322802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-03-06. Estimated completion is 2020-12-01.
What conditions does trial NCT01322802 study?
This clinical trial studies the following conditions: Stage IV Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Ovarian Germ Cell Tumor.
What interventions are being tested in trial NCT01322802?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01322802?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01322802 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Ovarian Epithelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI